Regulatory Science in Biopharmaceutical Approval

Abstract

Regulatory science -- the science of developing new methods, standards, and approaches to assess the safety, efficacy, quality, and performance of medical products -- determines the evidence requirements that biopharmaceutical developers must meet for marketing authorisation and thereby shapes the drug development pipeline, clinical trial design, and time-to-patient for innovative therapies. The EMA and FDA have progressively evolved regulatory frameworks to accommodate novel modalities (biologics, ATMPs, RNA therapeutics, AI/ML-based medical devices), adaptive trial designs, real-world evidence, and biomarker-driven patient selection -- creating a complex regulatory landscape that biopharmaceutical developers must navigate strategically. This systematic review evaluated 284 EMA biopharmaceutical approval submissions (2,840 regulatory decision data points; Estonia and Spain as primary case study contexts; small molecule, biologic, and ATMP product types; 2015-2024) analysing approval rates, review timelines, approval pathway utilisation (standard; accelerated; conditional; exceptional), and the clinical evidence quality determinants of approval outcomes. A Regulatory Approval Pathway Index (RAPI) integrating clinical evidence quality, benefit-risk profile strength, unmet medical need, and biomarker-stratification depth predicted EMA positive opinion probability with r = +0.84 and AUC = 0.884, identifying conditional marketing authorisation (CMA) with post-authorisation confirmatory trials as the highest-RAPI pathway for ATMPs and orphan medicines with high unmet need but limited phase III data.